Suppr超能文献

造血干细胞动员不良的定义、发生率、危险因素及其对自体移植结局的影响。

Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation.

机构信息

Department of Internal Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, Heidelberg, Germany.

出版信息

Biol Blood Marrow Transplant. 2010 Apr;16(4):490-9. doi: 10.1016/j.bbmt.2009.11.012. Epub 2009 Nov 17.

Abstract

As more efficient agents for stem cell mobilization are being developed, there is an urgent need to define which patient population might benefit from these novel drugs. For a precise and prospective definition of "poor mobilization" (PM), we have analyzed the efficiency of mobilization in patients intended to receive autologous transplantation at our center in the past 6 years. Between January 2003, and December 2008, 840 patients with the following diagnoses were scheduled to undergo leukapheresis: multiple myeloma (MM, n = 602) and non-Hodgkin lymphoma (NHL, n= 238). Most patients mobilized readily: close to 85% of the patients had a level of 20/microL to >500/microL of CD34(+) cells at the peak of stimulation. Of the 840 patients, 129 (15.3%) were considered to be PMs, defined as patients who had a peak concentration of <20/microL of CD34(+) cells upon stimulation with granulocyte-colony stimulating factor (G-CSF) subsequent to induction chemotherapy appropriate for the respective disease. Among them, 38 (4.5%) patients had CD34(+) levels between 11 and 19/microL at maximum stimulation, defined as "borderline" PM, 49 (5.8%) patients had CD34(+) levels between 6 and 10/microL, defined as "relative" PM, and 42 patients (5%) with levels of <5/microL, defined as "absolute" PM. There was no difference in the incidence of PM between patients with MM versus those with NHL. Sex, age, body weight (b.w.) and previous irradiation therapy did not make any significant difference. Only the total number of cycles of previous chemotherapy (P = .0034), and previous treatment with melphalan (Mel; P = .0078) had a significant impact on the ability to mobilize. For the good mobilizers, the median time to recovery of the white blood cells (WBCs) to 1.0/nL or more was 13 days with a range of 7 to 22 days, whereas for the PM group it was 14 days with a range of 8 to 37 days. This difference was statistically not significant. The median time to recovery of the platelets counts to an unmaintained level of >20/nL was 11 days with a range of 6 to 17 days for the good mobilizers, whereas for the PM it was 11 days with a range of 7 to 32 days. Again, this difference was not significant. The majority of the patients today intended for autologous transplantations were able to mobilize readily. As long as > or =2.0 x 10(6) of CD34(+) cells/kg b.w. have been collected, PM was not associated with inferior engraftment.

摘要

随着更有效的干细胞动员剂的开发,迫切需要定义哪些患者群体可能受益于这些新型药物。为了精确和前瞻性地定义“动员不良”(PM),我们分析了过去 6 年在我们中心接受自体移植的患者的动员效率。2003 年 1 月至 2008 年 12 月,840 例患有以下诊断的患者计划接受白细胞分离术:多发性骨髓瘤(MM,n=602)和非霍奇金淋巴瘤(NHL,n=238)。大多数患者容易动员:近 85%的患者在刺激的高峰期有 20/μL 至>500/μL 的 CD34+细胞水平。在 840 例患者中,有 129 例(15.3%)被认为是 PMs,定义为在诱导化疗后用粒细胞集落刺激因子(G-CSF)刺激时 CD34+细胞峰值<20/μL 的患者。其中,38 例(4.5%)患者在最大刺激时 CD34+水平在 11 至 19/μL 之间,定义为“边缘”PM,49 例(5.8%)患者 CD34+水平在 6 至 10/μL 之间,定义为“相对”PM,42 例(5%)患者水平<5/μL,定义为“绝对”PM。MM 患者与 NHL 患者之间 PM 的发生率没有差异。性别、年龄、体重(b.w.)和先前的放疗治疗没有造成任何显著差异。只有先前化疗的总周期数(P=0.0034)和先前使用美法仑(Mel;P=0.0078)治疗有显著影响动员能力。对于良好动员者,白细胞(WBC)恢复到 1.0/nL 或更高水平的中位数时间为 13 天,范围为 7 至 22 天,而对于 PM 组为 14 天,范围为 8 至 37 天。这种差异无统计学意义。血小板计数恢复到>20/nL 的中位数时间对于良好动员者为 11 天,范围为 6 至 17 天,而对于 PM 组为 11 天,范围为 7 至 32 天。同样,这种差异没有统计学意义。今天,大多数打算接受自体移植的患者都能够顺利动员。只要采集到>或=2.0 x 10(6)个 CD34+细胞/kg b.w.,PM 与植入不良无关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验